Camelot-2: A phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A rearrangements or NPM1 mutations, Who Are Ineligible for Intensive Chemotherapy

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Elias Joseph Jabbour, David A. Sallman, Deborah Briseno-Toomey, Christina Drenberg Guttke, Xiaojun Huang, Richard James Dillon, Lucille A. Ferrante, Takayuki Ikesoe, Angélique Langlois, Christina Loefgren, Boaz Nachmias, Ayelet Nelson
+10 more Kathryn E. Packman, Prathap Nagaraja Shastri, Christian Récher, Gail J. Roboz, Natasha Schuier, Meena Thayu, Danielle Trancucci, Athena F. Zuppa, Christoph Röllig, Andrew H. Wei
DOI: 10.1016/j.jtct.2025.12.574
Cited by: 0

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S401–S402
Publication date
1 February 2026
Language
EN